# Deciphera Pharmaceuticals (Ono)

Source: https://onco.cc/companies/deciphera/  
OnCo record `deciphera` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Kinase-switch-control company behind ripretinib for GIST and vimseltinib for tenosynovial giant cell tumour; bought by Ono Pharmaceutical in 2024.

## Summary

Deciphera Pharmaceuticals, based in Waltham, Massachusetts, is the kinase-switch-control company behind ripretinib for gastrointestinal stromal tumour and vimseltinib for tenosynovial giant cell tumour, and it was bought by Ono Pharmaceutical in 2024 for around 2.4 billion dollars. Ripretinib, sold as Qinlock, was approved in 2020 on the INVICTUS trial, with INTRIGUE and INSIGHT following, and vimseltinib, sold as Romvimza, was approved on 14 February 2025 on the MOTION trial. OnCo links it to GIST, soft tissue sarcomas and tenosynovial giant cell tumour, and to both drug records. Whether switch-control inhibition yields further drugs beyond these two rare indications is the open question now that it sits inside a Japanese pharma. Ripretinib and vimseltinib have their own pages.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: Waltham, MA
- Type: biotech
- Website: https://www.deciphera.com

## Sources

- Official website: https://www.deciphera.com

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Tenosynovial giant cell tumour (TGCT)](https://onco.cc/cancers/tenosynovial-giant-cell-tumour/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Inlexisertib](https://onco.cc/drugs/inlexisertib/), [Ripretinib](https://onco.cc/drugs/ripretinib/), [Vimseltinib](https://onco.cc/drugs/vimseltinib/)
- trials: [A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)](https://onco.cc/trials/nct06630234/), [A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor](https://onco.cc/trials/nct04078295/), [A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies](https://onco.cc/trials/nct05957367/), [A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.](https://onco.cc/trials/nct07734116/), [A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib](https://onco.cc/trials/nct03673501/), [A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)](https://onco.cc/trials/nct05144854/), [A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ](https://onco.cc/trials/nct06948448/), [A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)](https://onco.cc/trials/nct06256328/), [INSIGHT](https://onco.cc/trials/insight-gist/), [INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)](https://onco.cc/trials/nct07429266/), [INVICTUS](https://onco.cc/trials/invictus/), [MOTION](https://onco.cc/trials/motion/), [Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer](https://onco.cc/trials/nct03036098/), [Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor](https://onco.cc/trials/nct03069469/)

---
JSON: https://onco.cc/api/v1/entities/deciphera.json